Real-time Estimate
Cboe BZX
09:39:05 06/06/2024 pm IST
5-day change
1st Jan Change
24.12
USD
-0.52%
+2.84%
+6.18%
Presenter SpeechDaniel Brennan (Analysts)Welcome. Day 2 of the TD Cowen Healthcare Conference....
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Avantor, Inc. Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-30-2024 08:00 AM
30/05
Transcript : Avantor, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM
14/05
RBC Capital Adjusts Price Target on Avantor to $30 From $29, Maintains Outperform Rating
29/04
MT
Baird Trims Price Target on Avantor to $26 From $27, Maintains Outperform Rating
29/04
MT
Transcript : Avantor, Inc., Q1 2024 Earnings Call, Apr 26, 2024
26/04
Avantor's Q1 Adjusted Earnings, Net Sales Fall
26/04
MT
North American Morning Briefing : Tech Still in -2-
26/04
DJ
Avantor, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
26/04
CI
Earnings Flash (AVTR) AVANTOR AND FINANCIAL NEWS Reports Q1 Revenue $1.68B, vs. Street Est of $1.68B
26/04
MT
Earnings Flash (AVTR) AVANTOR AND FINANCIAL NEWS Reports Q1 EPS $0.09, vs. Street Est of $0.20
26/04
MT
Deutsche Bank Adjusts Price Target on Avantor to $25 From $23, Keeps Hold Rating
18/04
MT
Beauty Health Names Sheri Lewis as Chief Supply Chain, Operations Officer
10/04
MT
Evercore ISI Raises Avantor's Price Target to $28 From $26, Maintains Outperform Rating
04/04
MT
Avantor, Inc. Announces Christi Shaw, Member of the Board of Directors, Will Not Stand for Re-Election
30/03
CI
Transcript : Avantor, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM
05/03
How long will this bullish phase last?
26/02
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...
26/02
Citigroup Adjusts Price Target on Avantor to $30 From $24, Maintains Buy Rating
15/02
MT
JPMorgan Adjusts Price Target on Avantor to $29 From $26, Maintains Overweight Rating
15/02
MT
UBS Adjusts Avantor Price Target to $29 From $25, Maintains Buy Rating
15/02
MT
Barclays Adjusts Price Target on Avantor to $27 From $24, Maintains Overweight Rating
15/02
MT
Baird Adjusts Price Target on Avantor to $26 From $25, Maintains Outperform Rating
15/02
MT
RBC Lifts PT on Avantor to $29 From $28, Says Execution Outshines Guidance, Remains Among Best Ideas in 2024; Keeps Outperform Rating
15/02
MT
Avantor, Inc. Provides Earnings Guidance for the First Quarter for the First Quarter and Full Year 2024
14/02
CI
Transcript : Avantor, Inc., Q4 2023 Earnings Call, Feb 14, 2024
14/02
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Avantor, Inc. is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education and government, and advanced technologies & applied materials industries. Its products include materials and consumables, equipment and instrumentation, and services and specialty procurement. Materials and consumables include chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, freezers, biological safety cabinets and critical environment supplies. Services and specialty procurement include onsite lab and production, clinical, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
More about the company
Last Close Price
24.24
USD
Average target price
27.8
USD
Spread / Average Target
+14.69%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1